An interventional study of Knee-hip Powered Soft Exoskeleton (MyoSuit, MyoSwiss, Zurich, Switzerland) in Muscular Dystrophies, Congenital Myopathy and Idiopathic Inflammatory Myopathies, sponsored by Institut de Myologie, France. Completed at 1 site in France. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Institut de Myologie, France · Not applicable, Interventional, and Other
The aims of the current study are as follow:
i) Evaluate the safety, usability, and acute efficiency of a powered knee-hip dermoskeleton (MyoSuit, MyoSwiss, Zurich, Switzerland) in patients with neuromuscular disorders, ii) Elaborate recommendations regarding usability criteria for safe and efficient use the device in patients with neuromuscular disorders (e.g. type and severity of patient's functional deficits), iii) generate necessary data to foresee a future study involving a home use of the device and assessment of long-term benefits.
Patients with neuromuscular disorders display different type of symptoms depending on the type of pathology. Diseases like facioscapulohumeral dystrophy (FSHD), limb-girdle muscular dystrophy (LGMD2b), sporadic inclusion body myositis (SIBM) or Pompe disease (PD) are characterized by severe muscle weakness leading to reduced functional capacities. This leads to a dramatic decrease of quality of life (e.g. reduced autonomy/participation, social isolation, depression) associated with increased fall risk and complications (e.g. trauma, cardio-vascular issues, trauma, chronic pain, loss of bone mass, and weight gain).
However, a residual of level of strength and residual function may be maintained over years, even at severe disease stages allowing transfers and ambulation. However, the maintenance of this type of activity is often associated with substantial compensatory movements, leading to high load on joints, orthopedic complications, and high fall-risk.
In contrast to traditional passive assistive devices such as orthoses, powered assistive devices, frequently termed dermo- or exoskeletons, have a very high potential for compensating muscle weakness and regain mobility and independence. Devices such as the ReWalk or the Indego use rigid structures, in parallel to the user's legs, and electric motors to stabilize the human against gravity during standing and walking. Thus far, these systems have been used mostly in clinical environments for gait rehabilitation in neurological conditions (e.g. spinal cord injury, post-stroke syndrome). Their weight, which can range from 13 to 48 kg , can make them difficult to use and transport, thus limiting their applicability beyond clinical environments. However, for assistive devices to be used in everyday life, they must provide assistance across activities of daily living (ADLs) in an unobtrusive manner.
Wearable motion assistance systems, especially those dedicated to lower limbs are highly promising for ambulant patients with neuromuscular disorders (e.g. FSHD, LGMD, SIBM or PD). In these conditions, the prevalence of lower-limb muscle weakness, in particular in proximal muscle groups (i.e. providing strength/torque to hips and knees) is very high. Schmidt et al. recently introduced a powered knee-hip soft exoskeleton (the Myosuit), a soft, wearable device designed to provide continuous assistance at the hip and knee joint when working with and against gravity in ADLs. This robotic device combines active and passive elements with a closed-loop force controller designed to behave like an external muscle (exomuscle) and deliver gravity compensation to the user. With 5.6 kg including batteries, the Myosuit is one of the lightest untethered devices capable of delivering gravity support to the user's knee and hip joints. In healthy subject, the Myosuit has been shown to effectively assist its users in gravity-intensive ADLs, such as sitting transfers. However, the effect of the device on movement parameters and user perception must be clarified. We believe that ambulant patients with neuromuscular disorders can highly benefit from a system that provides mobility assistance like the Myosuit. The use of such a device has the potential to shift the loss of ambulation/transfer abilities to a higher age and might mitigate disease progression and occurrence of complications. Whether the Myosuit may be safe, usable, and efficient in ambulant patients with neuromuscular disorders, remain to be specifically investigated.
548 studies on the registry are indexed under Muscular Dystrophies; 89 are open to participants now.
This study's enrollment of 32 is above the median of 24 across 344 interventional studies indexed under Muscular Dystrophies.
Browse Muscular Dystrophies studies →Institut de Myologie, France is the lead sponsor of 29 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Confirmed diagnosis of a pathology belonging to one of the following family*:
Primary disorders of muscles
Metabolic disorders
Functional capacities:
Exclusion Criteria:
Patients and healthy subjects will use a Knee-hip Powered Soft Exoskeleton to perform different standardised tasks
Device: Knee-hip Powered Soft Exoskeleton (MyoSuit, MyoSwiss, Zurich, Switzerland)
Patients and healthy subjects will perform different standardised tasks without Knee-hip Powered Soft Exoskeleton
Patients and healthy subjects will wear the movement assistance device to perform different standardised physical evaluations.
Absence of adverse effect attributable to the use of the device during task performed within a knee-hip powered soft exoskeleton
Time frame: Through study completion, on average 4 weeks
Variation in the 2 Minutes Walking Test distance (express in meters) when performed using versus not using the device
Time frame: Visit 2 and 3, on average 2 weeks
Variation in the 10 Meters Walking Test performance (express in seconds) when performed using versus not using the device
Time frame: Visit 2 and 3, on average 2 weeks
Difference of performance with and without the device during 30 Sit To Stand
Time frame: Visit 2 and 3, on average 2 weeks
Difference of performance with and without the device during simple Sit To Stand
Time frame: Visit 2 and 3, on average 2 weeks
Difference of performance with and without the device during the squating test
Time frame: Visit 2 and 3, on average 2 weeks
Difference of performance with and without the device during Time Up & Go test
Time frame: Visit 2 and 3, on average 2 weeks
Difference of performance with and without the device during stairs climbing test
Time frame: Visit 2 and 3, on average 2 weeks
Variation in spatiotemporal gait parameters during the 2 Minutes Walking Test with and without the device using 3D accelerometers' system
Spatiotemporal gait parameters: Cadence, Gait Speed, Step Duration, Stride Length, Cadence Asymmetry, Gait Speed Asymmetry, Stance Asymmetry, Stride Length Asymmetry
Time frame: Visit 2 and 3, on average 2 weeks
Variation in spatiotemporal gait parameters during the 10 Meters Walking Test with and without the device using 3D accelerometers' system
Spatiotemporal gait parameters: Cadence, Gait Speed, Step Duration, Stride Length, Cadence Asymmetry, Gait Speed Asymmetry, Stance Asymmetry, Stride Length Asymmetry
Time frame: Visit 2 and 3, on average 2 weeks
Variation in kinematics parameters during 30 Sit To Stand with and without the device using 3D accelerometers' system
Kinematics parameters: Gait Joint Angles, Stick Plot Visualization - Sagital plane, Hip-Knee \& Knee-Ankle Plots
Time frame: Visit 2 and 3, on average 2 weeks
Variation in kinematics parameters during unique Sit To Stand with and without the device using 3D accelerometers' system
Kinematics parameters: Gait Joint Angles, Stick Plot Visualization - Sagital plane, Hip-Knee \& Knee-Ankle Plots
Time frame: Visit 2 and 3, on average 2 weeks
Variation in kinematics parameters during Time Up & Go evaluation with and without the device using 3D accelerometers' system
Kinematics parameters: Gait Joint Angles, Stick Plot Visualization - Sagital plane, Hip-Knee \& Knee-Ankle Plots
Time frame: Visit 2 and 3, on average 2 weeks
Variation in kinematics parameters during stairs climbing test with and without the device using 3D accelerometers' system
Kinematics parameters: Gait Joint Angles, Stick Plot Visualization - Sagital plane, Hip-Knee \& Knee-Ankle Plots
Time frame: Visit 2 and 3, on average 2 weeks
Modification of lower limb muscle recruitment measured by surface EMG with and without the device
Time frame: Visit 2 and 3, on average 2 weeks
Variation in postural stability measured by force platform with and without the device
Mean Velocity, RMS Sway
Time frame: Visit 2 and 3, on average 2 weeks
Modification in scoring of the device measured by the Modified Nordic Questionnaire
Time frame: Through study completion, on average 4 weeks
Positive scoring of device efficiency measured by the System usability scale
Time frame: Through study completion, on average 4 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut de Myologie, France